Are you a media representative looking for content on Bayer? This section provides access to media releases as well as feeds from our social media channels.

June 24, 2020

Bayer announces agreements to resolve major legacy Monsanto litigation

Company will make a total payment of $10.1 billion to $10.9 billion (€9.1 billion to €9.8 billion) to resolve current and address potential future Roundup™ litigation/ • Company also resolves dicamba drift litigation for payment of up to $400 million and most PCB water litigation exposure for payment of approximately $820 million/ • Funding sourced from free cash flow and Animal Health divestment /• Bayer is well positioned to deliver science-based solutions to meet global health, nutrition needs Read more
June 17, 2020

Non-metastatic castration resistant prostate cancer treatment NUBEQA® (darolutamide) significantly improves overall survival with a favourable safety profile in men with non-metastatic prostate cancer

Read more
April 21, 2020

Bayer partners with Population Health Research Institute (PHRI) on major global research study on COVID-19 treatments

Read more
March 26, 2020

Bayer Scholarships for Students Now Accepting Applications for 2020

Over $125,000 in scholarships available to Canadian students across two programs/ • Canadian agriculture needs bright minds across many disciplines/ • Application deadlines in April and June Read more
February 27, 2020

ALTAIR study published confirming efficacy of EYLEA® treat and extend dosing regimens for patients with wet AMD

Read more
February 25, 2020

New treatment for men with non-metastatic castration resistant prostate cancer approved in Canada

Read more
February 13, 2020

Updated results of Phase III trial show darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer

Full data to be presented at upcoming scientific meeting Read more
December 03, 2019

Bayer to help young leaders fight food insecurity

Young Canadian leaders return from Youth Ag Summit in Brazil with global perspective for tackling the UN Sustainable Development Goals Read more
November 15, 2019

Bayer responds to decision by the Institut national d’excellence en santé et en services sociaux (INESSS) for VITRAKVI® (larotrectinib); reaffirms commitment to Canadian TRK fusion cancer patients

Read more
November 06, 2019

Bayer responds to coverage recommendation by the Pan-Canadian Oncology Drug Review (pCODR) for VITRAKVI® (larotrectinib); reaffirms commitment to Canadian TRK fusion cancer patients

Read more